[8-K] Merck & Co., Inc. Reports Material Event

Rhea-AI Filing Summary

Merck & Co., Inc. (MRK) furnished an 8-K under Item 2.02, providing an earnings press release for the third quarter of 2025 as Exhibit 99.1 and additional supplemental materials as Exhibit 99.2. The company states this information is being furnished and is not deemed filed under Section 18 of the Exchange Act.

The filing also includes Exhibit 104 (Cover Page Interactive Data File). Merck’s common stock trades on the NYSE under MRK.

false 0000310158 0000310158 2025-10-30 2025-10-30 0000310158 us-gaap:CommonStockMember 2025-10-30 2025-10-30 0000310158 mrk:Sec1.875NotesDue2026Member 2025-10-30 2025-10-30 0000310158 mrk:Sec3.250NotesDue2032Member 2025-10-30 2025-10-30 0000310158 mrk:Sec2.500NotesDue2034Member 2025-10-30 2025-10-30 0000310158 mrk:Sec1.375NotesDue2036Member 2025-10-30 2025-10-30 0000310158 mrk:Sec3.500NotesDue2037Member 2025-10-30 2025-10-30 0000310158 mrk:Sec3.700NotesDue2044Member 2025-10-30 2025-10-30 0000310158 mrk:Sec3.750NotesDue2054Member 2025-10-30 2025-10-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) October 30, 2025 (October 30, 2025)

Merck & Co., Inc.

(Exact name of registrant as specified in its charter)

New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission File Number) 22-1918501 (I.R.S. Employer Identification No.)

126 East Lincoln Avenue, Rahway, NJ (Address of principal executive offices) 07065 (Zip Code)

Registrant’s telephone number, including area code (908) 740-4000

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock ($0.50 par value)		MRK		New York Stock Exchange
1.875% Notes due 2026		MRK/26		New York Stock Exchange
3.250% Notes due 2032		MRK/32		New York Stock Exchange
2.500% Notes due 2034		MRK/34		New York Stock Exchange
1.375% Notes due 2036		MRK 36A		New York Stock Exchange
3.500% Notes due 2037		MRK/37		New York Stock Exchange
3.700% Notes due 2044		MRK/44		New York Stock Exchange
3.750% Notes due 2054		MRK/54		New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

Item 2.02. Results of Operations and Financial Condition.

The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.

Incorporated by reference is a press release issued by Merck & Co., Inc. on October 30, 2025, regarding earnings for the third quarter of 2025, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.

This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

	(d) Exhibits
	Exhibit 99.1	Press release issued October 30, 2025, regarding earnings for the third quarter of 2025
	Exhibit 99.2	Certain supplemental information not included in the press release
	Exhibit 104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Merck & Co., Inc.
Date: October 30, 2025	By:	/s/ Kelly E. W. Grez
		Kelly E. W. Grez
		Corporate Secretary

FAQ

What did Merck (MRK) disclose in this 8-K?

Merck furnished an Item 2.02 update with a Q3 2025 earnings press release (Exhibit 99.1) and supplemental information (Exhibit 99.2).

Are the Q3 2025 materials considered filed or furnished?

They are furnished and are not deemed filed under Section 18 of the Exchange Act.

Which exhibits are included with Merck’s 8-K?

Exhibit 99.1 (press release), Exhibit 99.2 (supplemental info), and Exhibit 104 (Cover Page Interactive Data File).

What is the period covered by the earnings release mentioned?

The materials relate to third quarter 2025.

When was the report dated?

The report is dated October 30, 2025.

Where is Merck’s common stock listed and what is the symbol?

Merck’s common stock is listed on the New York Stock Exchange under the symbol MRK.

Which 8-K item applies to this disclosure?

It is under Item 2.02 – Results of Operations and Financial Condition.